BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease.

The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-molecule and biological drug candidates. One major target has been the β-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BACE-1 inhibitors. The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD treatment. It also suggests new possibilities for discovering BACE-1-targeted compounds with more complex mechanisms of actions and improved efficacy. Herein, we review the major advances in BACE-1 drug discovery, from single-target small molecule inhibitors to multitarget compounds. We discuss these compounds as innovative tools for better understanding the complexity of AD and for identifying efficacious drug candidates to treat this devastating disease.

[1]  William Greenlee,et al.  Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. , 2012, Journal of medicinal chemistry.

[2]  Hemant R. Jadhav,et al.  Design, synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors. , 2016, Bioorganic & medicinal chemistry.

[3]  M. Fielden,et al.  Retinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat , 2015, Toxicologic pathology.

[4]  Arun K. Ghosh,et al.  The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors. , 2013, Current topics in medicinal chemistry.

[5]  C. Maycock,et al.  Peptidomimetic β-Secretase Inhibitors Comprising a Sequence of Amyloid-β Peptide for Alzheimer's Disease. , 2015, Journal of medicinal chemistry.

[6]  Migliore Amico.  Ensemble-docking approach on BACE-1 : Pharmacophore Perception and Guidelines for Drug Design , .

[7]  D. Case,et al.  Constant pH molecular dynamics in generalized Born implicit solvent , 2004, J. Comput. Chem..

[8]  M L Bolognesi,et al.  Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. , 1998, Journal of medicinal chemistry.

[9]  O. Firuzi,et al.  Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors. , 2013, Bioorganic & medicinal chemistry.

[10]  Paola Bisignano,et al.  Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments , 2016, ChemMedChem.

[11]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[12]  Jonathan W. Essex,et al.  Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments , 2010, J. Chem. Inf. Model..

[13]  David S. Goodsell,et al.  Protein Flexibility in Virtual Screening: The BACE-1 Case Study , 2012, J. Chem. Inf. Model..

[14]  Xiao Mei Zheng,et al.  An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities. , 2015, ACS medicinal chemistry letters.

[15]  G. Vigers,et al.  Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species. , 2013, Journal of medicinal chemistry.

[16]  Xiao Mei Zheng,et al.  Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. , 2014, Journal of medicinal chemistry.

[17]  Shankar Venkatraman,et al.  Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[18]  Adrian E Roitberg,et al.  Enhancing Conformation and Protonation State Sampling of Hen Egg White Lysozyme Using pH Replica Exchange Molecular Dynamics. , 2012, Journal of chemical theory and computation.

[19]  M. Bolognesi,et al.  From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease? , 2016, Journal of medicinal chemistry.

[20]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[21]  R. Swerdlow,et al.  A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. , 2004, Medical hypotheses.

[22]  A. Good,et al.  Macrocyclic prolinyl acyl guanidines as inhibitors of β-secretase (BACE). , 2015, Bioorganic & medicinal chemistry letters.

[23]  Erik Lindström,et al.  Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1. , 2010, Biochemistry.

[24]  A. Simon,et al.  Methyl-substitution of an iminohydantoin spiropiperidine β-secretase (BACE-1) inhibitor has a profound effect on its potency. , 2015, Bioorganic & medicinal chemistry letters.

[25]  E. Novellino,et al.  A stereoselective approach to peptidomimetic BACE1 inhibitors. , 2013, European journal of medicinal chemistry.

[26]  F. J. Luque,et al.  Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. , 2014, Journal of medicinal chemistry.

[27]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[28]  Jonathan B Baell,et al.  Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS). , 2016, Journal of natural products.

[29]  K. Scearce-Levie,et al.  8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. , 2014, Journal of medicinal chemistry.

[30]  Andrea Armirotti,et al.  Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. , 2015, Angewandte Chemie.

[31]  Xiongwei Zhu,et al.  Alzheimer's disease: the two-hit hypothesis , 2004, The Lancet Neurology.

[32]  A. Cavalli,et al.  Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors. , 2016, Journal of medicinal chemistry.

[33]  Lynn A. Hyde,et al.  Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates. , 2016, Journal of medicinal chemistry.

[34]  J. Macor,et al.  Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors. , 2016, Journal of medicinal chemistry.

[35]  V. Andrisano,et al.  Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography. , 2016, Journal of medicinal chemistry.

[36]  F. J. Luque,et al.  Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. , 2009, Journal of medicinal chemistry.

[37]  David L Mobley,et al.  Alchemical free energy methods for drug discovery: progress and challenges. , 2011, Current opinion in structural biology.

[38]  K. Parris,et al.  Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design. , 2015, Journal of medicinal chemistry.

[39]  Andrea Mcclure,et al.  Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents. , 2016, ACS medicinal chemistry letters.

[40]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[41]  Yan Niu,et al.  4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis, biological evaluation and docking studies. , 2014, European journal of medicinal chemistry.

[42]  Qin Jiang,et al.  Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. , 2016, Journal of medicinal chemistry.

[43]  Hwangseo Park,et al.  Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. , 2003, Journal of the American Chemical Society.

[44]  Karl Herrup,et al.  The case for rejecting the amyloid cascade hypothesis , 2015, Nature Neuroscience.

[45]  Andrea Cavalli,et al.  Combining Dyad Protonation and Active Site Plasticity in BACE-1 Structure-Based Drug Design , 2012, J. Chem. Inf. Model..

[46]  Laura Pérez-Benito,et al.  Application of Free Energy Perturbation for the Design of BACE1 Inhibitors , 2016, J. Chem. Inf. Model..

[47]  B. Forsberg,et al.  Traffic-Related Air Pollution and Dementia Incidence in Northern Sweden: A Longitudinal Study , 2015, Environmental health perspectives.

[48]  W. Park,et al.  Synthesis of (3S,4S)-4-aminopyrrolidine-3-ol derivatives and biological evaluation for their BACE1 inhibitory activities. , 2016, Bioorganic & medicinal chemistry letters.

[49]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[50]  J. B. Jordan,et al.  Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase. , 2016, Journal of medicinal chemistry.

[51]  A. Cavalli,et al.  Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms. , 2015, Accounts of chemical research.

[52]  Tímea Polgár,et al.  Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. , 2005, Journal of medicinal chemistry.

[53]  A. Cavalli,et al.  From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold. , 2015, Bioorganic & medicinal chemistry letters.

[54]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[55]  A. Cavalli,et al.  Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease , 2013, PloS one.

[56]  E. Yamashita,et al.  Evaluation of transition-state mimics in a superior BACE1 cleavage sequence as peptide-mimetic BACE1 inhibitors. , 2015, Bioorganic & medicinal chemistry.

[57]  K. Scearce-Levie,et al.  Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous system. , 2014, Journal of medicinal chemistry.

[58]  A. Cavalli,et al.  Computational methods in the discovery and design of BACE-1 inhibitors. , 2012, Current medicinal chemistry.

[59]  J. Hardy,et al.  A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.

[60]  Li Tang,et al.  Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities. , 2011, Bioorganic & medicinal chemistry.

[61]  C. Lemere.  Immunotherapy for Alzheimer’s disease: hoops and hurdles , 2013, Molecular Neurodegeneration.

[62]  M. Geng,et al.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease , 2011, Acta Pharmacologica Sinica.

[63]  J. Pandit,et al.  Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors , 2015, Journal of medicinal chemistry.

[64]  Suresh Babu,et al.  Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.

[65]  P. Rosenthal,et al.  Development of protease inhibitors for protozoan infections , 2008, Current opinion in infectious diseases.

[66]  A. Cavalli,et al.  3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. , 2003, Journal of medicinal chemistry.

[67]  M. Carmen Villaverde,et al.  Effect of pH and ligand charge state on BACE-1 fragment docking performance , 2013, Journal of Computer-Aided Molecular Design.

[68]  S. Hitchcock,et al.  Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease. , 2015, Bioorganic & medicinal chemistry letters.

[69]  R. Dean,et al.  The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans , 2015, The Journal of Neuroscience.

[70]  Wei Wang,et al.  Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. , 2009, Bioorganic & medicinal chemistry.

[71]  Christian Haass,et al.  Games Played by Rogue Proteins in Prion Disorders and Alzheimer's Disease , 2003, Science.

[72]  Maurizio Recanatini,et al.  A small molecule targeting the multifactorial nature of Alzheimer's disease. , 2007, Angewandte Chemie.

[73]  M. Rosales-Hernández,et al.  Asp32 and Asp228 determine the selective inhibition of BACE1 as shown by docking and molecular dynamics simulations. , 2016, European journal of medicinal chemistry.

[74]  J. Macor,et al.  Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[75]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[76]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[77]  B. Vissel,et al.  Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease , 2014, Acta neuropathologica communications.

[78]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[79]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[80]  Arun K. Ghosh,et al.  BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. , 2014, Chemical Society reviews.

[81]  L. Polito,et al.  3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease. , 2015, ACS chemical neuroscience.

[82]  Rajeev Prabhakar,et al.  Protonation States of the Catalytic Dyad of β-Secretase (BACE1) in the Presence of Chemically Diverse Inhibitors: A Molecular Docking Study , 2012, J. Chem. Inf. Model..

[83]  Sirpa Hartikainen,et al.  Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors , 2015, PloS one.

[84]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[85]  R. Wahl,et al.  Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718). , 2014, Journal of medicinal chemistry.

[86]  Christopher R. Ellis,et al.  pH-Dependent Population Shift Regulates BACE1 Activity and Inhibition. , 2015, Journal of the American Chemical Society.

[87]  K. P. Kepp,et al.  Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[88]  Christopher R. Ellis,et al.  Constant pH Molecular Dynamics Reveals pH-Modulated Binding of Two Small-Molecule BACE1 Inhibitors. , 2016, The journal of physical chemistry letters.

[89]  D. Timm,et al.  Preparation and biological evaluation of conformationally constrained BACE1 inhibitors. , 2015, Bioorganic & medicinal chemistry.

[90]  Brian McKittrick,et al.  Discovery of potent iminoheterocycle BACE1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[91]  D. Desiderio,et al.  Design, Synthesis, and Evaluation of Donepezil-Like Compounds as AChE and BACE-1 Inhibitors. , 2016, ACS medicinal chemistry letters.

[92]  A. Cavalli,et al.  Role of Molecular Dynamics and Related Methods in Drug Discovery. , 2016, Journal of medicinal chemistry.

[93]  Yuan Cheng,et al.  From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). , 2011, Journal of medicinal chemistry.

[94]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[95]  A. Cavalli,et al.  Fluorinated benzophenone derivatives: balanced multipotent agents for Alzheimer's disease. , 2014, European journal of medicinal chemistry.

[96]  Laura Pérez-Benito,et al.  Acylguanidine Beta Secretase 1 Inhibitors: A Combined Experimental and Free Energy Perturbation Study. , 2017, Journal of chemical theory and computation.

[97]  Ó. Delgado,et al.  1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. , 2015, Journal of medicinal chemistry.

[98]  A. Cavalli,et al.  Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. , 2008, Bioorganic & medicinal chemistry letters.

[99]  Romano Silvestri,et al.  Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease , 2009, Medicinal research reviews.

[100]  Arun K. Ghosh,et al.  Structure-based design, synthesis and biological evaluation of novel β-secretase inhibitors containing a pyrazole or thiazole moiety as the P3 ligand. , 2015, Bioorganic & medicinal chemistry letters.

[101]  Jayme L. Dahlin,et al.  The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.

[102]  James Andrew McCammon,et al.  Conformational Dynamics and Binding Free Energies of Inhibitors of BACE-1: From the Perspective of Protonation Equilibria , 2015, PLoS Comput. Biol..

[103]  Wei Yang,et al.  Air Pollution, Oxidative Stress, and Alzheimer's Disease , 2012, Journal of environmental and public health.

[104]  Michael Czarniecki,et al.  Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.

[105]  Ruben Abagyan,et al.  Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. , 2009, Journal of medicinal chemistry.

[106]  Paul Zuck,et al.  Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. , 2008, Journal of medicinal chemistry.

[107]  Bernard R Brooks,et al.  pH replica‐exchange method based on discrete protonation states , 2011, Proteins.

[108]  Hemant R. Jadhav,et al.  Rational design, synthesis and in vitro evaluation of allylidene hydrazinecarboximidamide derivatives as BACE-1 inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[109]  Arun K. Ghosh,et al.  Developing β‐secretase inhibitors for treatment of Alzheimer’s disease , 2012, Journal of neurochemistry.